Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 26.

Huber, M; Metzner, K J; Geissberger, F D; Shah, C; Leemann, C; Klimkait, T; Böni, J; Trkola, A; Zagordi, O (2017). MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. Journal of Virological Methods, 240:7-13.

Zhou, Q; Uhlig, K M; Muth, A; Kimpel, J; Lévi, C; Münch, R C; Seifried, J; Pfeiffer, A; Trkola, A; Coulibaly, C; von Laer, D; Wels, W S; Hartwig, U F; Verhoeyen, E; Buchholz, C J (2015). Exclusive transduction of human CD4+ T Cells upon systemic delivery of CD4-targeted lentiviral vectors. Journal of Immunology, (195):2493-2501.

Trkola, A (2014). Potency needs constancy. Nature, 514(7523):442-443.

Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Schmid, P; Schultze, D; Schöni-Affolter, F; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2013). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Medicine, 14(4):195-207.

Riedel, T; Ghasparian, A; Moehle, K; Rusert, P; Trkola, A; Robinson, J A (2011). Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. ChemBioChem, 12(18):2829-2836.

Wunderli, W; Meerbach, A; Guengoer, T; Berger, C; Greiner, O; Caduff, R; Trkola, A; Bossart, W; Gerlach, D; Schibler, M; Cordey, S; McKee, T A; Van Belle, S; Kaiser, L; Tapparel, C (2011). Astrovirus infection in hospitalized infants with severe combined immunodeficiency after allogeneic hematopoietic stem cell transplantation. PLoS ONE, 6(11):e27483.

Rusert, P; Krarup, A; Magnus, C; Brandenberg, O F; Weber, J; Ehlert, A K; Regoes, R R; Günthard, H F; Trkola, A (2011). Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. Journal of Experimental Medicine, 208(7):1419-1433.

Ruprecht, C R; Krarup, A; Reynell, L; Mann, A M; Brandenberg, O F; Berlinger, L; Abela, I A; Regoes, R R; Günthard, H F; Rusert, P; Trkola, A (2011). MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Journal of Experimental Medicine, 208(3):439-454.

Joos, B; Rieder, P; Fischer, M; Kuster, H; Rusert, P; Trkola, A; Pillai, S K; Wong, J K; Weber, R; Günthard, H F (2010). Association between specific HIV-1 Env traits and virologic control in vivo. Infection, Genetics and Evolution, 10(3):365-372.

Haas, A; Rehr, M; Graw, F; Rusert, P; Bossart, W; Kuster, H; Trkola, A; Günthard, H F; Oxenius, A (2010). HIV-1 replication activates CD4+ T cells with specificities for persistent herpes viruses. EMBO Molecular Medicine, 2(6):231-244.

Pugach, P; Krarup, A; Gettie, A; Kuroda, M; Blanchard, J; Piatak Jr, M; Lifson, J D; Trkola, A; Robbiani, M (2010). In vivo binding and retention of CD4-specific DARPin 57.2 in macaques. PLoS ONE, 5(8):e12455.

Seitz, M; Rusert, P; Moehle, K; Trkola, A; Robinson, J A (2010). Peptidomimetic inhibitors targeting the CCR5-binding site on the human immunodeficiency virus Type-1 gp120 glycoprotein complexed to CD4. Chemical Communications, 46(41):7754-7756.

Abela, I A; Reynell, L; Trkola, A (2010). Therapeutic antibodies in HIV treatment - classical approaches to novel advances. Current Pharmaceutical Design, 16(33):3754-3766.

Magnus, C; Rusert, P; Bonhoeffer, S; Trkola, A; Regoes, R R (2009). Estimating the stoichiometry of HIV entry. Journal of Virology, 83(3):1523-1531.

Rusert, P; Mann, A; Huber, M; von Wyl, V; Gunthard, H F; Trkola, A (2009). Divergent effects of cell environment on HIV entry inhibitor activity. AIDS, 23(11):1319-1327.

Mann, A M; Rusert, P; Berlinger, L; Kuster, H; Günthard, H F; Trkola, A (2009). HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS, 23(13):1659-1667.

Günthard, H F; Huber, M; Kuster, H; Shah, C; Schüpbach, J; Trkola, A; Böni, J (2009). HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. Clinical Infectious Diseases, 48(11):e117-e120.

Trkola, A; Kuster, H; Rusert, P; von Wyl, V; Leemann, C; Weber, R; Stiegler, G; Katinger, H; Joos, B; Günthard, H F (2008). In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. Journal of Virology, 82(3):1591-1599.

Frost, D W; Trkola, A; Günthard, H F; Richman, D D (2008). Antibody responses in primary HIV-1 infection. Current Opinion in HIV and AIDS, 3(1):45-51.

Huber, M; Olson, W C; Trkola, A (2008). Antibodies for HIV treatment and prevention: window of opportunity? Current Topics in Microbiology and Immunology, 317:39-66.

Schweizer, A; Rusert, P; Berlinger, L; Ruprecht, C R; Mannhart, A; Corthésy, S; Turville, S G; Aravantinou, M; Fischer, M; Robbiani, M; Amstutz, P; Trkola, A (2008). CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathogens, 4(7):e1000109.

Joos, B; Fischer, M; Kuster, H; Pillai, S K; Wong, J K; Böni, J; Hirschel, B; Weber, R; Trkola, A; Günthard, H F (2008). HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 105(43):16725-16730.

Huber, M; von Wyl, V; Ammann, C G; Kuster, H; Stiegler, G; Katinger, H; Weber, R; Fischer, M; Stoiber, H; Günthard, H F; Trkola, A (2008). Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. Journal of Virology, 82(8):3834-3842.

Joos, B; Fischer, M; Schweizer, A; Kuster, H; Böni, J; Wong, J K; Weber, R; Trkola, A; Gunthard, H F (2007). Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions. Journal of Infectious Diseases, 196(2):313-320.

Aceto, L; Karrer, U; Grube, Ch; Oberholzer, R; Hasse, B; Presterl, E; Böni, J; Kuster, H; Trkola, A; Weber, R; Günthard, H F (2005). Die akute HIV-1-Infektion in Zürich: 2002–2004. Praxis, 94(32):1199-1205.

Joos, B; Trkola, A; Fischer, M; Kuster, H; Rusert, P; Leemann, C; Böni, J; Oxenius, A; Price, D A; Phillips, R E; Wong, J K; Hirschel, B; Weber, R; Günthard, H F (2005). Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. Journal of Virology, 79(14):9026-9037.

This list was generated on Thu Sep 19 04:06:22 2019 CEST.